Company intelligence / Profile preview

Gene Signal International SA

Lausanne, Vaud, Switzerlandgenesignal.com ↗
Ownership
Private
Development stage
Other
01

Overview

Gene Signal developed a pipeline focused on modulating angiogenesis using antisense oligonucleotides, proteins, and monoclonal antibodies. Its lead product, aganirsen (GS‑101), an antisense oligonucleotide eye drop for neovascular-associated corneal graft rejection (NV-CGR), completed or nearly completed Phase III trials by 2013. Additional programs were in Phase II or discovery for other ophthalmic and vascular indications. The company has demonstrated preclinical efficacy in models of retinal neovascular disease and ischemic retinopathy.

Therapeutic areas
OphthalmologyOncologyCardiovascularDermatology
Modalities
Antisense oligonucleotidesProteinsMonoclonal antibodies
Industry
Biotech
02

Drug pipeline

1 asset

aganirsen

3
03

Partnerships

No major pharmaceutical partnerships publicly disclosed as of last available information. The company expressed intent to seek pharma partners for further development/commercialization.

Beyond the preview

Go deeper on Gene Signal International SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gene Signal International SA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call